Long-acting Drug Delivery Formulation Platforms and Technologies

A mid-sized, global pharmaceutical company is seeking novel formulation approaches and technologies that enable sustained drug delivery. Specifically, the company is interested in approaches allowing for once-weekly dosing from oral and transdermal delivered drugs, and long-acting injectable platforms (intravenous, intramuscular, and subcutaneous) that permit 4–6-month dosing regimens.

Approaches of interest

• Small molecule drug compound formulations
• Wide range of delivery approaches including nanoparticles, gastro-retentive gels, transdermal patches, and implants
• Solutions with information on ease of manufacture, regulatory requirements, and safety data
• Platforms applicable to multiple disease areas and drug compounds
   

Out of scope

• Approaches that cannot be applied to small molecules
• Active drug delivery devices, such as pumps
   

Developmental stage of interest: Opportunities from preclinical stage onwards that have pharmacokinetic validation with a model compound. Opportunities with in vivo data will be prioritized.
 

Please note: Full RFP is attached in the "More Information" section of this page. Faculty and researchers interested in applying for these opportunities based on technologies developed or disclosed at Vanderbilt must submit their proposals through the CTTC.